Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Will pay $1.85 billion upfront and pair Opdivo and Yervoy with Nektar's NKTR-214
February 16, 2018
By: Tim Wright
Editor-in-Chief, Contract Pharma
Bristol-Myers Squibb (BMS) has signed a whopping $3.6 billion deal to pair its Opdivo and Yervoy with Nektar’s NKTR-214 in a range of tumor types. The two companies have agreed to co-develop NKTR-214 in combination with PD-1 antagonist Opdivo (nivolumab) and CTLA4 inhibitor Yervoy (ipilimumab) in more than 20 indications across nine cancers, including melanoma, renal cell carcinoma, non-small-cell lung cancer, bladder cancer and triple-negative breast cancer. Pivotal trials in RCC and melanoma are due to start before the end of the year. BMS is paying $1.85 billion upfront, with another $1.43 billion in the offing if the alliance passes development and regulatory milestones and another $250 million if it meets sales targets. The companies will share global profits on NKTR-214, with Nektar receiving 65% and BMS 35%. “We are excited to bring our leading capabilities and expertise in developing cancer therapies together with Nektar’s innovative science to jointly develop and commercialize NKTR-214 in combination with Opdivo and Opdivo plus Yervoy,” said Giovanni Caforio, chairman and chief executive officer, BMS. “Bristol-Myers Squibb has established Opdivo plus Yervoy as the only approved immunotherapy combination for cancer patients and built a robust oncology pipeline. With this commitment to the development of NKTR-214, an investigational therapy designed with a unique approach to harnessing the full potential of the interleukin-2 pathway, we now have a third validated I-O mechanism that has demonstrated a clinical benefit in patients, and holds significant potential to expand the benefits that these immuno-oncology agents can bring to patients with cancer.” The two companies have been working together on NKTR-214 since 2016, when they signed an agreement to test Opdivo and NKTR-214 in a phase I/II trial in bladder, RCC and NSCLC. NKTR-214 is a CD122-biased agonist designed to stimulate the patient’s own immune system to fight cancer, working to expand T cell and natural killer (NK) cell populations that attack tumors as well as increasing PD-1 expression on cancer cells. “Bristol-Myers Squibb, the global leader in immuno-oncology, is the ideal collaborator to enable us to establish NKTR-214 as a backbone immunotherapy in the treatment of cancer,” said Howard Robin, president and chief executive officer, Nektar. “NKTR-214’s ability to grow tumor infiltrating lymphocytes (TILs) in vivo and replenish the immune system is critically important as many patients battling cancer lack sufficient TIL populations to benefit from approved checkpoint inhibitor therapies. This strategic collaboration allows us to very quickly develop NKTR-214 with the leading approved PD-1 immune checkpoint inhibitor in numerous registrational trials. We look forward to our continued relationship with Bristol-Myers Squibb as we work together to advance cancer treatment for patients around the world.” Under the terms of the deal, BMS will fund upwards of two thirds of the clinical programs, on a scale depending on whether it is testing one or both of its drugs, and it will lead the global commercialization of regimens that include NKTR-214, with Nektar retaining co-marketing rights in the U.S., major EU markets and Japan.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !